<DOC>
	<DOCNO>NCT00539383</DOCNO>
	<brief_summary>This phase 1 , multi-centre , sequential cohort , open-label , dose-escalation study safety , tolerability , PK ANG1005 patient solid tumor ( without brain metastasis ) . ANG1005 give IV infusion every 21 day ( 1 treatment cycle ) . Each patient participate 1 dose group receive 6 cycle treatment provide evidence tumor progression , recovery ≤Grade 1 baseline nonhematologic , ANG1005-related toxicity ( except alopecia ) , absolute neutrophil count ≥1.5 x 109/L , platelet count ≥100 x 109/L .</brief_summary>
	<brief_title>A Phase 1 , Open-Label , Dose Escalation Study ANG1005 Patients With Advanced Solid Tumors Metastatic Brain Cancer</brief_title>
	<detailed_description>This phase 1 , multi-centre , sequential cohort , open-label , dose-escalation study safety , tolerability , PK ANG1005 patient solid tumor ( without brain metastasis ) . ANG1005 give IV infusion every 21 day ( 1 treatment cycle ) . Each patient participate 1 dose group receive 6 cycle . Patients may receive additional cycle ANG1005 evidence tumor progression , recovery ≤Grade 1 baseline nonhematologic , ANG1005-related toxicity ( except alopecia ) , absolute neutrophil count ≥1.5 x 109/L , platelet count ≥100 x 109/L . Initially , cohorts 1 - 3 patient enrol dose group . Dose escalation dose double do first 3 dose group follow modified Fibonacci dose escalation scheme increase 67 % , 50 % , 40 % 33 % thereafter . If 1 patient cohort experience emergent ≥ Grade 2 drug-related toxicity first treatment cycle , minimum 3 patient enrol , subsequent cohort ( ) dose double stop applicable . If &gt; 1 patient cohort experience dose limit toxicity ( DLT ) first treatment cycle , define follow treatment-emergent least possibly related ANG1005 : ) Any Grade 3 4 nonhematologic toxicity , ii ) Febrile neutropenia , iii ) Grade 4 neutropenia ≥7 day duration , and/or iv ) Any Grade 4 thrombocytopenia , dose escalation stop prior dos explore maximum tolerate dose ( MTD ) , dose-level ≤1 6 patient cohort develop emergent DLT ) . Once MTD establish , approximately 14 patient enrol dose-level order ass safety tolerability ANG1005 , PK profile ANG1005 MTD , preliminary anti-tumor activity ANG1005 patient solid tumor ( without brain metastasis ) .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>1 . Written inform consent 2 . Histologically cytologically confirm metastatic advancestage solid tumor progress follow standard therapy , opinion Investigator , standard effective therapy available ; patient without brain metastasis may enrol doseescalation part study 3 . Patients enrol expanded MTD cohort must show unequivocal evidence brain metastasis 4 . Male female patient . 5 . Age ≥18 year 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 7 . An expected survival least 3 month 8 . Measurable disease accord RECIST criterion ; patient brain metastasis must least one measurable lesion brain , accord RECIST criterion 9 . Male female subject surgically sterile postmenopausal must agree use reliable method birth control duration study 90 day last dose study drug administration ; male partner female subject use condom duration study , 90 day last dose study drug administration 1 . Chemotherapy , radiotherapy ( except palliative radiation deliver &lt; 20 % bone marrow ) , investigational agent within 4 week first dose study drug . Biologic therapy ( 13cisretinoic acid , thalidomide , tamoxifen , celebrex , erlotinib , imatinib , vorinostat , lapatinib ) immunotherapy ( interferon b , cdx110 ( EGFR vIII vaccine ) , interleukin 2 , thalidomide ) within 1 week first dose study drug . Bevacizumab within 6 week first dose study drug 2 . Pregnant lactating female 3 . Any acute viral , bacterial , fungal infection require parenteral therapy within 14 day prior study treatment 4 . Known severe hypersensitivity paclitaxel 5 . Severe toxicity previous taxane treatment 6 . Treatment P450 CYP 3A4 CYP 2C8 enzymeinducing anticonvulsant drug within 14 day prior treatment study drug 7 . Patients inadequate hematological , liver , renal function 8 . Known suspected acute chronic active Hepatitis B , Hepatitis C , HIV/AIDS 9 . Patients unstable uncompensated respiratory , cardiac , hepatic renal disease organ system dysfunction , medical condition , laboratory abnormality , opinion Investigator , would either comprise patient 's safety interfere evaluation test material 10 . Evidence persistent Grade 2 great neurotoxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Brain metastasis</keyword>
</DOC>